ADMA Biologics receives FDA approval for eight plasma collection center

ADMA Biologics announced that it has received U.S. Food and Drug Administration, FDA, approval for its eighth ADMA BioCenters plasma collection facility located in Hammond, Louisiana. This plasma collection facility commenced operations and initiated source plasma collection in the second quarter of 2022. With the FDA approval announced today, this facility is now licensed to collect, and introduce into interstate commerce, human source plasma for further manufacturing in the U.S. "The successful expansion of ADMA’s plasma collection network supports the Company’s goal of plasma supply self-sufficiency, ongoing revenue growth objectives, and further supports the pathway towards profitability. The approval is a testament to the BioCenters team’s tireless commitment, and we thank the FDA for its efforts and expeditious review of the Hammond, LA Biologics License Application, which came in advance of ADMA’s anticipated approval date," said Adam Grossman, President and Chief Executive Officer of ADMA.